Lpath Inc.

Lpath Inc. is the leader in the discovery and development of monoclonal antibodies targeting bioactive lipids that contribute to disease. With its ImmuneY2 drug-discovery engine and robust patent estate, Lpath is the only company able to generate therapeutic antibodies that neutralize bioactive lipids. As such, the company is uniquely well positioned in the rapidly growing universe of lipid-focused companies. At present, Lpath has two antibody therapeutics in phase 2 clinical trials.